Genmab Announces Financial Results for the First Quarter of 2017
May 10, 2017; Copenhagen, Denmark; Interim Report for the First Quarter of 2017 Highlights USD 255 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 211 million DARZALEX received positive opinion from European regulatory …